Takeda Pharmaceutical (TAK) Other Operating Expenses (2019 - 2025)

Takeda Pharmaceutical's Other Operating Expenses history runs 6 years deep, the most recent figure standing at $1.1 billion for Q4 2025.

• On a quarterly basis, Other Operating Expenses rose 10.54% year-over-year to $1.1 billion in Q4 2025; TTM through Mar 2026 was -$711.0 million, a 95.58% increase from a year earlier, with the FY2025 full-year figure at -$7.0 billion, up 6.61% from the prior year.
• Other Operating Expenses advanced to $1.1 billion in Q4 2025 per TAK's latest filing, from -$2.7 billion in the prior quarter.
• Across five years, Other Operating Expenses topped out at $1.3 billion in Q4 2022 and bottomed at -$16.1 billion in Q1 2024.
• The 4-year median for Other Operating Expenses is $953.0 million (2024), against an average of -$2.1 billion.
• Across the five-year window, Other Operating Expenses rose 17.86% in 2023 and sank 1409.64% in 2024, its largest moves.
• Year by year, Other Operating Expenses stood at $1.3 billion in 2022, then fell by 10.94% to $1.1 billion in 2023, then decreased by 16.99% to $953.0 million in 2024, then advanced by 10.54% to $1.1 billion in 2025.
• Per Business Quant, the three latest TAK Other Operating Expenses figures stand at $1.1 billion (Q4 2025), -$2.7 billion (Q3 2025), and $908.6 million (Q2 2025).